Russian company offers Ho Chi Minh City drugs for COVID-19 treatment

The Vietnam Fatherland Front (VFF) Committee of Ho Chi Minh City on November 25 received 10,000 ampoules of Cytoflavin donated by the Polysan Science & Technology Company in Russia’s Saint-Petersburg to aid the local treatment of COVID-19 patients.

At the handover ceremony of 10,000 ampoules of Cytoflavin donated by the Russian company. (Photo: VNA)
At the handover ceremony of 10,000 ampoules of Cytoflavin donated by the Russian company. (Photo: VNA)

The ampoules, worth over 1.2 billion VND (over 88,000 USD) will be distributed among eight local medical facilities and hospitals.

Speaking at the handover ceremony, Timur S. Sadykov, Russian Consul General in the city, stressed that joint activities against the pandemic between Vietnam and Russia – including experience exchanges and donations of medical supplies and vaccine – reflected the two nations’ comprehensive strategic partnership and their peoples’ friendship and solidarity.

The diplomat took the occasion to thanks the municipal authorities for supporting Russian citizens staying in the city during the latest outbreak of the pandemic. He hoped the drug will assist the local medical sector in treating the patients.

Expressing her gratitude for the valuable and timely support, Chairwoman of the municipal VFF Committee To Thi Bich Chau said the aid is proof of the Vietnam – Russia comprehensive strategic partnership as well as of the sound cooperative relationship between Ho Chi Minh City and Saint Petersburg.

Cytoflavin is used as part of Russia’s treatment regimen for cardiovascular and brain complications in COVID-19 patients, bringing positive results so far. In Vietnam, the drug, licensed by the Ministry of Health, is prescirbed for acute stroke patients. The use of Cytoflavin for patients with COVID-19 helps reduce post-COVID-19 neurological complications.

The batch of 10,000 ampoules for Ho Chi Minh City marked the third time the drug has been given to Vietnam by the Russian side.